Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 32Gastrointestinal 1

Conditions

Colorectal Neoplasms 77Pancreatic Neoplasms 56Stomach Neoplasms 52Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Neoplasm Metastasis 25Colonic Neoplasms 23Neoplasms 15Cholangiocarcinoma 13Liver Neoplasms 10Gastrointestinal Neoplasms 10Breast Neoplasms 9Adenocarcinoma Of Esophagus 9Carcinoma, Hepatocellular 7Anus Neoplasms 7Lung Neoplasms 6Head and Neck Neoplasms 6Biliary Tract Neoplasms 6Ovarian Neoplasms 5Melanoma 5Adenocarcinoma 5Kidney Neoplasms 4Gastrointestinal Diseases 4Digestive System Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Lymphoma 3

Interventions

pembrolizumab 49Nivolumab 21Cisplatin 11Cetuximab 11Carboplatin 10Paclitaxel 8Gemcitabine 8Docetaxel 8atezolizumab 7Ipilimumab 7Cyclophosphamide 7spartalizumab 6durvalumab 6Fluorouracil 6Capecitabine 6fludarabine 5avelumab 5Albumin-Bound Paclitaxel 5cemiplimab 4Trastuzumab 4Taxes 4Oxaliplatin 4Leucovorin 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3tisotumab vedotin 3aldesleukin 3Specimen Handling 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Drug Therapy × Gastrointestinal × Clear all
NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Merus B.V.

Phase 1/2 Active not recruiting
194 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡